Literature DB >> 20546898

The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae.

Leslie Evans1, Miranda Hughes, Joanne Waters, Jason Cameron, Neil Dodsworth, David Tooth, Anthony Greenfield, Darrell Sleep.   

Abstract

An expression system is described for the production of monomeric scFvs and scFv antibody fragments genetically fused to human albumin (at either the N- or C-terminus or both). Based upon strains of Saccharomyces cerevisiae originally developed for the production of a recombinant human albumin (Recombumin) this system has delivered high levels of secreted product into the supernatant of shake flask and high cell density fed-batch fermentations. Specific binding to the corresponding ligand was demonstrated for each of the scFvs and scFv-albumin fusions and pharmacokinetic studies showed that the fusion products had greatly extended circulatory half-lives. The system described provides an attractive alternative to other microbial systems for the manufacture of this type of product. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546898     DOI: 10.1016/j.pep.2010.05.009

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  10 in total

Review 1.  Lepidopteran cells, an alternative for the production of recombinant antibodies?

Authors:  Martine Cérutti; Josée Golay
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

2.  Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin.

Authors:  Esben G W Schmidt; Michael L Hvam; Filipa Antunes; Jason Cameron; Dorthe Viuff; Birgitte Andersen; Nanna N Kristensen; Kenneth A Howard
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

3.  Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.

Authors:  Jan Terje Andersen; Bjørn Dalhus; Dorthe Viuff; Birgitte Thue Ravn; Kristin Støen Gunnarsen; Andrew Plumridge; Karen Bunting; Filipa Antunes; Rebecca Williamson; Steven Athwal; Elizabeth Allan; Leslie Evans; Magnar Bjørås; Søren Kjærulff; Darrell Sleep; Inger Sandlie; Jason Cameron
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

Review 4.  IL-1Ra and its delivery strategies: inserting the association in perspective.

Authors:  Muhammad Sajid Hamid Akash; Kanwal Rehman; Shuqing Chen
Journal:  Pharm Res       Date:  2013-06-22       Impact factor: 4.200

5.  A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation.

Authors:  Karen Kræmmer Schelde; Karl Nicholls; Frederik Dagnæs-Hansen; Karen Bunting; Helen Rawsthorne; Birgitte Andersen; Christopher J A Finnis; Miranda Williamson; Jason Cameron; Kenneth A Howard
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

6.  Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics.

Authors:  Jan Terje Andersen; Jason Cameron; Andrew Plumridge; Leslie Evans; Darrell Sleep; Inger Sandlie
Journal:  J Biol Chem       Date:  2013-07-01       Impact factor: 5.157

7.  Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor.

Authors:  Jan Terje Andersen; Bjørn Dalhus; Jason Cameron; Muluneh Bekele Daba; Andrew Plumridge; Leslie Evans; Stephan O Brennan; Kristin Støen Gunnarsen; Magnar Bjørås; Darrell Sleep; Inger Sandlie
Journal:  Nat Commun       Date:  2012-01-03       Impact factor: 14.919

Review 8.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.

Authors:  Kine Marita Knudsen Sand; Malin Bern; Jeannette Nilsen; Hanna Theodora Noordzij; Inger Sandlie; Jan Terje Andersen
Journal:  Front Immunol       Date:  2015-01-26       Impact factor: 7.561

9.  Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.

Authors:  Emma Davé; Ralph Adams; Oliver Zaccheo; Bruce Carrington; Joanne E Compson; Sarah Dugdale; Michael Airey; Sarah Malcolm; Hanna Hailu; Gavin Wild; Alison Turner; James Heads; Kaushik Sarkar; Andrew Ventom; Diane Marshall; Mark Jairaj; Tim Kopotsha; Louis Christodoulou; Miren Zamacona; Alastair D Lawson; Sam Heywood; David P Humphreys
Journal:  MAbs       Date:  2016-08-17       Impact factor: 5.857

10.  Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion.

Authors:  Mengyuan Liu; Yi Huang; Lei Hu; Guoping Liu; Xueping Hu; Dongxu Liu; Xiaosong Yang
Journal:  BMC Biotechnol       Date:  2012-09-25       Impact factor: 2.563

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.